Modern treatments with highly active antiretroviral therapy (HAART) regimens result in HIV suppression and immune recovery, however the prevalence of HIV-Associated Neurocognitive Disorders (HAND) and neurodegeneration has remained the same or increased. During the previous period of funding we showed that abnormal activation of cyclin dependent kinase-5 (CDK5) plays a key role in HIV. We also demonstrated that abnormal activation of CDK5 promotes neurodegeneration via accumulation of TAU and collapsin response mediator protein-2 (CRMP2), a novel target in HAND. Remarkably, knockdown of CDK5 reduced the deficits in a gp120 tg model. For the renewal the main objectives will be;a) to better understand the cellular mechanisms through which HIV proteins promote nucleo-cytoplasmic translocation and pathological activation of CDK5 leading to TAU/CRMP2 mediated neurotoxicity, and b) to determine if TAU reduction or CDK5 inhibition with a new class of CDK5 inhibitors that penetrate the BBB is neuroprotective in preclinical models of HIV neurotoxicity. Our central hypothesis is that HIV proteins such as trans-activator of transcription (Tat) and gp120 modulate cell cycle regulators and interfere with the subcellular localization of CDK5. CDK5 nucleo-cytoplasmic translocation could promote the neurotoxic phosphorylation of CDK5 substrates such as TAU and CRMP2. Therefore strategies to modulate CDK5 or reduce TAU might represent novel therapeutic interventions for HAND. For this purpose we propose the following Aims:
Aim 1 : To elucidate the role of CDK5 translocation and TAU/CRMP2 phosphorylation in the cellular mechanisms of HIV neurotoxicity.
Aim 2 : To determine whether TAU reduction in vivo ameliorates the neurodegenerative and behavioral deficits in tg rodent models of HIV neurotoxicity.
Aim 3 : To evaluate the neuroprotective effects of novel and more specific CDK5 inhibitor which reduce TAU/CRMP2 phosphorylation in tg models of HIV neurotoxicity. This new direction represents a natural extension from the previous period of funding and provides a new avenue that might lead to the development of a novel class of HIV neuroprotective drugs. !

Public Health Relevance

Modern treatments with highly active antiretroviral therapy regimens result in HIV suppression and immune recovery, however the prevalence of HIV-Associated Neurocognitive Disorders (HAND) and neurodegeneration has not decreased, therefore, the management of HAND requires new therapies in order to address the toxic effects of HIV. For this project we propose to better understand the cellular mechanisms through which HIV proteins promote nucleo-cytoplasmic translocation and pathological activation of CDK5 leading to TAU/CRMP2 mediated neurotoxicity, and to determine whether TAU reduction or CDK5 inhibition is neuroprotective in preclinical models of HIV neurotoxicity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH062962-11
Application #
8325832
Study Section
NeuroAIDS and other End-Organ Diseases Study Section (NAED)
Program Officer
Colosi, Deborah
Project Start
2000-12-01
Project End
2017-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
11
Fiscal Year
2012
Total Cost
$367,828
Indirect Cost
$130,328
Name
University of California San Diego
Department
Pathology
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Eleuteri, Simona; Di Giovanni, Saviana; Rockenstein, Edward et al. (2015) Novel therapeutic strategy for neurodegeneration by blocking A? seeding mediated aggregation in models of Alzheimer's disease. Neurobiol Dis 74:144-57
Dhungel, Nripesh; Eleuteri, Simona; Li, Ling-Bo et al. (2015) Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on ?-synuclein. Neuron 85:76-87
Fields, Jerel; Dumaop, Wilmar; Langford, T D et al. (2014) Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders. J Neuroimmune Pharmacol 9:102-16
Mandler, Markus; Valera, Elvira; Rockenstein, Edward et al. (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol 127:861-79
Avraham, Hava Karsenty; Jiang, Shuxian; Fu, Yigong et al. (2014) The cannabinoid CBýýý receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J Pharmacol 171:468-79
Repunte-Canonigo, Vez; Lefebvre, Celine; George, Olivier et al. (2014) Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. Mol Neurodegener 9:26
Overk, Cassia R; Masliah, Eliezer (2014) Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol 88:508-16
Desplats, Paula; Dumaop, Wilmar; Smith, David et al. (2013) Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 80:1415-23
Fields, Jerel; Dumaop, Wilmar; Rockenstein, Edward et al. (2013) Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer. J Neurovirol 19:89-101
DeBoever, Christopher; Reid, Erin G; Smith, Erin N et al. (2013) Whole transcriptome sequencing enables discovery and analysis of viruses in archived primary central nervous system lymphomas. PLoS One 8:e73956

Showing the most recent 10 out of 32 publications